Multiparametric cardiovascular magnetic resonance assessment of cardiac allograft vasculopathy

Christopher A. Miller, Jaydeep Sarma, Josephine H. Naish, Nizar Yonan, Simon G. Williams, Steven M. Shaw, David Clark, Keith Pearce, Martin Stout, Rahul Potluri, Alex Borg, Glyn Coutts, Saqib Chowdhary, Gerry P. McCann, Geoffrey J M Parker, Simon G. Ray, Matthias Schmitt

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Objectives: This study sought to evaluate the diagnostic performance of multiparametric cardiovascular magnetic resonance (CMR) for detecting cardiac allograft vasculopathy (CAV) using contemporary invasive epicardial artery and microvascular assessment techniques as reference standards, and to compare the performance of CMR with that of angiography. Background: CAV continues to limit the long-term survival of heart transplant recipients. Coronary angiography has a Class I recommendation for CAV surveillance and annual or biannual surveillance angiography is performed routinely in most centers. Methods: All transplant recipients referred for surveillance angiography at a single UK center over a 2-year period were prospectively screened for study eligibility. Patients prospectively underwent coronary angiography followed by coronary intravascular ultrasound, fractional flow reserve, and index of microcirculatory resistance. Within 1 month, patients underwent multiparametric CMR, including assessment of regional and global ventricular function, absolute myocardial blood flow quantification, and myocardial tissue characterization. In addition, 10 healthy volunteers underwent CMR. Results: Forty-eight patients were recruited, median 7.1 years (interquartile range: 4.6 to 10.3 years) since transplantation. The CMR myocardial perfusion reserve was the only independent predictor of both epicardial (β = -0.57, p <0.001) and microvascular disease (β = -0.60, p <0.001) on stepwise multivariable regression. The CMR myocardial perfusion reserve significantly outperformed angiography for detecting moderate CAV (area under the curve, 0.89 [95% confidence interval (CI): 0.79 to 1.00] vs. 0.59 [95% CI: 0.42 to 0.77], p = 0.01) and severe CAV (area under the curve, 0.88 [95% CI: 0.78 to 0.98] vs. 0.67 [95% CI: 0.52 to 0.82], p = 0.05). Conclusions: CAV, including epicardial and microvascular components, can be detected more accurately using noninvasive CMR-based absolute myocardial blood flow assessment than with invasive coronary angiography, the current clinical surveillance technique. © 2014 by the American College of Cardiology Foundation Published by Elsevier Inc.
    Original languageEnglish
    Pages (from-to)799-808
    Number of pages9
    JournalJournal of the American College of Cardiology
    Volume63
    Issue number8
    DOIs
    Publication statusPublished - 4 Mar 2014

    Keywords

    • cardiac allograft vasculopathy
    • cardiovascular magnetic resonance
    • diagnosis
    • microvascular disease
    • myocardial blood flow

    Fingerprint

    Dive into the research topics of 'Multiparametric cardiovascular magnetic resonance assessment of cardiac allograft vasculopathy'. Together they form a unique fingerprint.

    Cite this